Management of Pregnancy-Induced Hypertension
Treat all pregnant women with blood pressure ≥140/90 mmHg (or ≥135/85 mmHg at home) with antihypertensive medications, targeting a diastolic BP of 85 mmHg and systolic BP of 110-140 mmHg to prevent severe maternal complications including stroke, organ damage, and progression to preeclampsia. 1
Immediate Management of Severe Hypertension
When BP exceeds 160/110 mmHg, this constitutes a hypertensive emergency requiring urgent treatment in a monitored setting within 15 minutes to prevent maternal stroke and other catastrophic complications 1, 2:
First-line agents for acute severe hypertension:
- Oral nifedipine (immediate-release)
- IV labetalol
- IV hydralazine
- Oral labetalol if IV access unavailable 1
Critical pitfall: Methyldopa should NOT be used for urgent BP reduction—it is too slow-acting for hypertensive emergencies 2.
Chronic Antihypertensive Management
For sustained BP ≥140/90 mmHg (office) or ≥135/85 mmHg (home), initiate oral antihypertensive therapy 1:
First-line oral agents:
- Methyldopa
- Labetalol
- Nifedipine (long-acting, only after 20 weeks)
- Oxprenolol 1
Second-line agents:
- Hydralazine
- Prazosin 1
Target BP: Diastolic 85 mmHg, systolic 110-140 mmHg. Reduce or stop medications if diastolic BP falls below 80 mmHg to avoid compromising uteroplacental perfusion 1.
Absolutely contraindicated: ACE inhibitors, ARBs, and direct renin inhibitors due to severe fetotoxicity 3.
Preeclampsia-Specific Management
Initial Assessment
Women with newly diagnosed preeclampsia require hospital assessment to determine stability. Stable patients may transition to outpatient management if reliable for BP monitoring and symptom reporting 1.
Seizure Prophylaxis
Magnesium sulfate is mandatory for women with:
- Proteinuria AND severe hypertension (≥160/110 mmHg)
- Neurological signs or symptoms (headache, visual changes, hyperreflexia, clonus) 1
Important warning: Do NOT give magnesium sulfate concurrently with calcium channel blockers due to risk of severe hypotension from synergistic effects 2.
Monitoring Protocol
Maternal monitoring:
- BP checks (frequency based on severity)
- Serial proteinuria assessment if not already present
- Clinical examination for clonus
- Laboratory tests twice weekly minimum:
- Hemoglobin
- Platelet count
- Liver enzymes
- Renal function (creatinine, uric acid)
Elevated uric acid correlates with worse maternal and fetal outcomes 1.
Fetal monitoring:
- Initial assessment to confirm well-being
- Serial ultrasound surveillance if fetal growth restriction present 1
Delivery Indications
Deliver at 37 weeks + 0 days gestation OR earlier if any of the following develop 1:
- Severe hypertension refractory to 3 antihypertensive classes
- Progressive thrombocytopenia
- Progressively abnormal liver or renal function tests
- Pulmonary edema
- Severe intractable headache, visual scotomata, or seizures
- Non-reassuring fetal status 1
Postpartum Management
Critical recognition: Up to 44% of pregnancy-related deaths from hypertensive disorders occur in the first 6 days postpartum 4. Hypertension can worsen or present de novo after delivery 5.
Postpartum antihypertensive agents safe for breastfeeding:
- Labetalol
- Nifedipine
- Enalapril
- Metoprolol 2
Recent evidence favors nifedipine over labetalol for postpartum BP control, with fewer readmissions 6.
Long-Term Cardiovascular Risk
Women with PIH have significantly increased lifetime cardiovascular disease risk. Essential components of postpartum care include 5, 7:
- Establishment of long-term medical follow-up
- Patient education about cardiovascular risks
- Promotion of healthy lifestyle modifications
- Preconception consultation for future pregnancies
- Low-dose aspirin (81 mg daily) starting at 12-16 weeks in subsequent pregnancies for preeclampsia prevention 4, 7
Key Clinical Pitfalls to Avoid
- Do not delay treatment of severe hypertension—confirm BP within 15 minutes and treat immediately 1
- Avoid over-treatment—stop antihypertensives if diastolic BP <80 mmHg to prevent uteroplacental insufficiency 1
- Never use ACE inhibitors/ARBs in pregnancy 3
- Do not combine magnesium sulfate with calcium channel blockers 2
- Do not assume hypertension resolves with delivery—maintain vigilant postpartum monitoring 5, 6